Declining birth rates, an aging global population, and rapidly evolving family structures are converging to reshape one of healthcare’s most personal and fastest-evolving sectors. New industry data shows the assisted reproductive technology market is projected to grow from USD 23.85 billion in 2024 to USD 35.14 billion by 2031, at a compound annual growth rate of 5.69%, as more individuals and couples worldwide turn to medical intervention to build their families.
Assisted reproductive technology, commonly abbreviated as ART, encompasses a range of medical procedures designed to help people conceive when facing fertility challenges — most notably in vitro fertilization (IVF), intrauterine insemination (IUI), gamete or embryo cryopreservation, and the use of donor eggs or sperm. These procedures typically involve manipulating eggs, sperm, or embryos outside the body to improve the odds of successful implantation and pregnancy, addressing underlying issues ranging from hormonal imbalances to genetic conditions.
A Demographic Story as Much as a Medical One
The forces driving ART demand are as much societal as they are clinical. Crude birth rates have been declining steadily across several major regions, a trend compounded by rapidly aging populations in many developed economies. At the same time, lifestyle factors long associated with reduced fertility — later marriage, higher stress levels, obesity, poor diet, smoking, and substance use — are becoming more prevalent globally, contributing to rising infertility rates even among younger populations.
Global health data indicates that roughly 11% of women who have previously given birth are unable to conceive again, while a smaller but still significant share of women of reproductive age are unable to have any live births at all, with infertility rates running notably higher in parts of Eastern Europe, North Africa, and the Middle East. That combination of demographic pressure and rising infertility prevalence is what underpins the market’s steady, structurally supported growth trajectory through the remainder of the decade.
- Global market valued at USD 22.80 billion in 2023, forecast to reach USD 35.14 billion by 2031
- In vitro fertilization (IVF) is the leading technique segment, valued at USD 16.60 billion in 2023
- Fertility clinics capture over 70% of the market by end user
- North America held roughly 33.5% of global market share in 2023
- Asia Pacific is the fastest-growing region, with a CAGR near 6.9% through 2031
IVF Technology Keeps Improving Success Rates
In vitro fertilization remains the largest and most closely watched technique category within the ART market, and its continued growth is being driven by genuine clinical progress rather than demand alone. Improved embryo culture systems, preimplantation genetic testing (PGT), and enhanced cryopreservation techniques are collectively pushing IVF success rates higher while enabling more individualized treatment protocols tailored to each patient’s specific fertility profile.
U.S. data illustrates the trend clearly: the number of babies born through IVF climbed from roughly 89,200 in 2021 to nearly 91,800 in 2022, with IVF now accounting for approximately 2.5% of all U.S. births — a meaningful and steadily growing share of the country’s total birth rate. As supportive regulatory frameworks and broader insurance coverage continue to lower the financial barrier to treatment, this upward trajectory in IVF utilization appears likely to continue.
Genomic Testing Enters the Mainstream
One of the more consequential clinical trends reshaping ART is the growing integration of genomic testing and personalized medicine into standard fertility treatment protocols. Preimplantation genetic testing allows clinicians to thoroughly examine embryos before implantation, identifying those with the highest likelihood of successful development while flagging potential genetic abnormalities early in the process.
By enabling more informed embryo selection, genomic screening techniques are measurably improving ART outcomes and reducing the risk of genetic disorders in offspring — a shift that reflects reproductive medicine’s broader move toward precision, individualized care.
This shift toward precision reproductive medicine is giving prospective parents more informed choices while simultaneously improving overall procedure success rates, a combination that is reinforcing patient confidence in ART as a viable and increasingly reliable path to parenthood.
Changing Family Structures Expand the Patient Base
Beyond clinical infertility, ART demand is being reshaped by evolving social norms around family formation. The rising prevalence of single-parent households and growing legal recognition of same-sex marriages are expanding the pool of individuals actively seeking reproductive technology services. As of recent tracking, same-sex marriage has become legal in more than 30 countries, with additional jurisdictions actively considering legislative or judicial action — a trend that is expected to continue widening the market’s addressable patient population over time.
North America’s Infrastructure, Asia Pacific’s Momentum
North America currently holds the largest regional share of the global ART market, supported by a well-developed healthcare system and one of the world’s largest networks of dedicated fertility clinics — U.S. federal health data has tracked several hundred such clinics nationwide. Continued product innovation, including advanced embryo culture media, has further reinforced the region’s leadership position.
Asia Pacific, meanwhile, is projected to be the fastest-growing region through 2031, driven by rising infertility rates, rapid urbanization, and increasingly supportive government policy. Several Asian governments have introduced direct subsidies for ART treatment, while a growing base of private fertility clinics and expanding international partnerships are improving accessibility across the region — factors that collectively position Asia Pacific as the primary growth frontier for the industry over the coming years.
Affordability Remains the Central Challenge
Cost remains the most significant barrier limiting broader ART adoption. IVF and its associated diagnostic testing carry substantial expense that varies considerably based on regional regulation and insurance coverage, placing treatment out of reach for many prospective patients. Industry players are responding by investing in cost-efficient technologies, expanding patient financing options, and lobbying for broader insurance coverage — efforts aimed at making ART accessible to a meaningfully wider population without compromising treatment quality or outcomes.
As demographic pressures, clinical innovation, and evolving social norms continue to reinforce one another, the assisted reproductive technology market is positioned for sustained, structurally supported growth through 2031 and beyond.
